.Competing enthusiasms.R.S., M.S., H.G. and also A.A.R. are planners of the 1M1M project. H.G. as well as A.A.R. are panel of supervisors members as well as R.S., M.S. and also A.A.R. are actually participants of the scientific advising committee of N1C. A.A.R. discloses work through LUMC, which has patents on exon-skipping technology, a number of which has been accredited to BioMarin and also ultimately sublicensed to Sarepta. As co-inventor of some of these patents, A.A.R. was entitled to a share of aristocracies. A.A.R. even more divulges acting as specialist for PTC Rehabs, Sarepta Therapeutics, Regenxbio, Dyne Rehabs, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and also Astra Zeneca. In the past 5 years, A.A.R. likewise did speaking to for Alpha Anomeric. A.A.R. likewise discloses subscription of the medical advisory boards of Eisai, Hybridize Therapies, Silence Therapeutics, Sarepta Therapies, Sapreme and Mitorx. In the past 5 years, A.A.R. was also a clinical advisory board participant for ProQR. Wage for A.A.R. u00e2 s consulting as well as recommending tasks is actually spent to LUMC. Over the last 5 years, LUMC additionally acquired sound speaker gratuity coming from PTC Therapeutics, Alnylam Netherlands, Italfarmaco as well as Pfizer as well as financing for arrangement investigation from Sapreme, Eisai, Galapagos, Synaffix and Alpha Anomeric. Job funding is actually acquired coming from Sarepta Therapies as well as Entrada through unlimited gives. H.G. has absolutely nothing to make known in regard to the subject matters dealt with in this particular document. Over the last 5 years, he has additionally gotten working as a consultant honoraria coming from UCB. M.S. received working as a consultant honoraria from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and Solaxa in the past 5 years, all irrelevant to the present manuscript. R.S. has absolutely nothing to divulge in relation to the subject matters dealt with in this manuscript. She has obtained speaker and/or working as a consultant gratuity or sponsoring payments coming from Abbvie, Bial, STADA as well as Everpharma over the last 5 years.